Editorial: Drug resistance in breast cancer – mechanisms and approaches to overcome chemoresistance

Raman, Dayanidhi; Cîmpean, Anca Maria; Miglio, Maria Rosaria De

doi:10.3389/fonc.2022.1080684

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several BC patients demonstrate inherent drug resistance, while others are initially drug-sensitive but develop resistance to anticancer treatments and commonly display multidrug resistance, which may cause recurrence and/or metastasis even though the prognosis for BC patients has significantly improved [86][87][88]. Nowadays, medication resistance is a significant factor in poor prognosis, lowering BC patients' survival rates [89].…”

Section: B7-h3 and Breast Cancer Drug Resistancementioning

confidence: 99%

A promising target for breast cancer: B7-H3

Jiang,

Liu,

Chen

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Breast cancer (BC) is the second-leading factor of mortality for women globally and is brought on by a variety of genetic and environmental causes. The conventional treatments for this disease have limitations, making it difficult to improve the lifespan of breast cancer patients. As a result, extensive research has been conducted over the past decade to find innovative solutions to these challenges. Targeting of the antitumor immune response through the immunomodulatory checkpoint protein B7 family has revolutionized cancer treatment and led to intermittent patient responses. B7-H3 has recently received attention because of its significant demodulation and its immunomodulatory effects in many cancers. Uncontrolled B7-H3 expression and a bad outlook are strongly associated, according to a substantial body of cancer research. Numerous studies have shown that BC has significant B7-H3 expression, and B7-H3 induces an immune evasion phenotype, consequently enhancing the survival, proliferation, metastasis, and drug resistance of BC cells. Thus, an innovative target for immunotherapy against BC may be the B7-H3 checkpoint.In this review, we discuss the structure and regulation of B7-H3 and its double costimulatory/coinhibitory function within the framework of cancer and normal physiology. Then we expound the malignant behavior of B7-H3 in BC and its role in the tumor microenvironment (TME) and finally focus on targeted drugs against B7-H3 that have opened new therapeutic opportunities in BC.

show abstract